Search clinical trials for: Bupropion 150 mg XL

Total 2424 results

Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

Healthy

United States
Massachusetts General Hospital

Completed

Neurobiological Underpinnings of Placebo Response in Depression

Depression

United States
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Healthy

United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Completed

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Breast Carcinoma | Cervical Carcinoma | Vaginal Carcinoma | Ovarian Carcinoma | Uterine Corpus Cancer | Vulvar Carcinoma | Postmenopausal

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Segraves, R., T., M.D., Ph.D.
GlaxoSmithKline

Completed

Female Orgasmic Disorder (FOD) and Wellbutrin XL

Orgasmic Disorder

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
GlaxoSmithKline

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers

Depressive Disorder, Major

China
Sandoz

Completed

A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

Depression
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Orexigen Therapeutics, Inc

Completed

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Obesity

United States
University of Rochester NCORP Research Base
National Cancer Institute (NCI)

Recruiting

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Be Diagnosed With Cancer and Have Completed Systemic Therapy

United States
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

Depression
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Teva Pharmaceuticals USA

Terminated

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Depressive Disorder

United States
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

Healthy

United States
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Healthy

Egypt
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Massachusetts General Hospital

Completed

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder

United States
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
HaEmek Medical Center, Israel

Unknown

The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study

Distal Ureterolithiasis

Israel
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
NeuroBo Pharmaceuticals Inc.

Completed

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

Hypercholesterolemia
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Vastra Gotaland Region

Recruiting

Varenicline and Bupropion for Alcohol Use Disorder

Alcohol Dependence | Alcoholism | Alcohol Use Disorder

Sweden
University of California, Los Angeles
National Institute of Mental Health (NIMH)

Completed

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Depression

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Warner Chilcott

Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Postmenopausal Osteoporosis

United States
Georgetown University

Unknown

Nilotinib in Huntington's Disease (Tasigna HD)

Huntington Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Cigarette Smoking-Related Carcinoma

United States
Bill & Melinda Gates Medical Research Institute

Not yet recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Healthy Volunteers

Kenya, Uganda
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Novartis Pharmaceuticals

Terminated

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma

Germany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
North Dakota State University
Neuropsychiatric Research Institute, Fargo, North Dakota

Completed

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

Roux en Y Gastric Bypass

United States
Chi-Un Pae
GlaxoSmithKline

Completed

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features (WellbutrinXL)

Depressive Disorder, Major

Korea, Republic of
AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
National Institute on Drug Abuse (NIDA)

Completed

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

Schizophrenia | Tobacco Use Disorder

United States
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Depression | Suicidal Ideation

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Healthy

United States
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland

Search clinical trials for: Bupropion 150 mg XL

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations